News
6d
Clinical Trials Arena on MSNDr. Falk Pharma’s PSC drug achieves endpoints in Phase III trialDr. Falk Pharma’s norucholic acid (NCA) drug has demonstrated potential in a Phase III trial for primary sclerosing ...
Pharmaceutical manufacturing sits at the intersection of science, technology, and global health—driving critical advances in how medicines are developed, produced, and delivered. News Medical ...
TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), ...
BERLIN, April 25, 2025--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of ...
BERLIN--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by ...
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers ...
Perform material- and labor-effective extrusion with Thermo Scientific™ Pharma 11 Twin-screw Extruder, which requires only a small amount of active pharmaceutical ingredient, operating at ...
Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating on Ascendis Pharma (ASND – Research Report) today and set a price target of $192.00. Discover outperforming stocks and ...
Scotiabank initiated coverage of UroGen Pharma (URGN) with an Outperform rating and $23 price target The company is developing a novel treatment for nonmuscle invasive bladder cancer, which the fi ...
NOT FOR DISSEMINATION IN OR INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HERZLIYA, Israel and CALGARY, AB, April 15, 2025 /PRNewswire/ -- Innocan Pharma Corporation (the ...
HERZLIYA, Israel and CALGARY, AB, April 15, 2025 /PRNewswire/ -- Innocan Pharma Corporation (the "Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has closed its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results